Poland· PL-100095256
Emadine
A emedastine product containing emedastinum, registered in Poland by Immedica Pharma AB. The same ATC class is registered in 12 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Emedastine is registered in 12 of 19 countries.
Countries holding a registration under ATC S01GX06 (emedastine), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Emedastine · ATC S01GX06
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
The record
At a glance
URPL (Poland)- Active substance
- Emedastinum
- Manufacturer
- Immedica Pharma AB
- Country
- Poland (PL)
- ATC code
- S01GX06
- ATC class
- Emedastine
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 4
- gtin05909990491711
- gtin05909990491728
- gtin05909990002030
- gtin05909990002047
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Emedastine in 6 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandEmadineImmedica Pharma AB
- SwedenEmadine 0,5 mg/ml Ögondroppar, lösningImmedica Pharma AB
- United KingdomEmadine 0.5mg/ml eye dropsNecessity Supplies Ltd
- SwitzerlandEmadine
- SpainEMADINE 0,5 MG/ML COLIRIO EN SOLUCIONAlcon Laboratories Ltd (Uk)
- NorwayEmadineImmedica Pharma AB (1)
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Emadine
- Liechtenstein · Emadine
- Norway · Emadine
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f6749eec-f767-4cdd-a7d1-f1412d5ed8de GET /v1/drugs/f6749eec-f767-4cdd-a7d1-f1412d5ed8de?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Krople do oczu, roztwór",
"source": "urpl",
"strength": "0,5 mg/ml",
"packaging": "05909990491711 ¦ Rp ¦ EU/1/98/095/001 ¦ 15790\n1 poj. 5 ml\n05909990491728 ¦ Rp ¦ EU/1/98/095/002 ¦ 15791\n1 poj. 10 ml\n05909990002030 ¦ Rp ¦ EU/1/98/095/003 ¦ 106947\n30 poj. 0,35 ml\n05909990002047 ¦ Rp ¦ EU/1/98/095/004 ¦ 106948\n60 poj. 0,35 ml",
"substance": "Emedastini difumaras 0.5 mg/ml",
"common_name": "Emedastinum",
"pl_product_id": "100095256",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about emedastine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.